APOB and metabolic syndrome: Despite the beneficial hepatic effect of FGF1, ApoB lipoprotein particles (especially LDL-cholesterol) are central to atherosclerosis development and even with effective LDL-cholesterol control, residual risk is prevalent in patients with metabolic syndrome.